Ipilimumab trials for Melanoma

All Ipilimumab trials · All Melanoma trials

Phase breakdown

Recruiting trials studying Ipilimumab for Melanoma

• A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
  NCT06581406 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 33 locations
• A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
  NCT06594991 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
  NCT06362369 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
  NCT04511013 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 331 locations
• Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
  NCT03340129 · Phase: Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 9 locations
• Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
  NCT06163820 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cryoablation+Ipilimumab+Nivolumab in Melanoma
  NCT05779423 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
  NCT04562129 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia
  NCT07422779 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
  NCT05896839 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
  NCT06240143 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
  NCT04697576 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
  NCT06365619 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
  NCT06295159 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
  NCT06683755 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
  NCT06743126 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 71 locations
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
  NCT05498792 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
  NCT07155317 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
  NCT06712927 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
  NCT07504796 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Ipilimumab for Melanoma?

21 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.